Soluble CD30 concentrations in ESRD patients with and without panel reactive HLA antibodies

Smita Vaidya, David Partlow, Titus Barnes, Phillip Thomas, Kristene Gugliuzza

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: In this retrospective study we compared accuracy of panel reactive antibodies (PRA) with serum soluble CD30 (sCD30) contents in predicting acute rejection crisis post-renal transplant. Methods: Pre-transplant sera from 115 patients were evaluated for their PRA and sCD30 concentrations. All patients received calcineurin inhibitorbased immunosuppressive therapy. Objective measurements for rejection were biopsy-proven acute rejection (AR) episodes within first six months of the transplant. Post-transplant sera of patients with AR were tested for the presence of donor-specific HLA antibodies (DSA). Results: Overall AR rate was 16% (18/115). Patients positive for PRA and sCD30 tests were at significantly higher risk for AVR compared with those patients negative for both the tests (36% vs. 5%, p = 0.01). Among negative PRA patients risk for AR was significantly elevated if they were also tested positive for sCD30 concentrations (21% vs. 5%, p = 0.04). Of the 18 patients with AR, 14 were positive for sCD30, and 13 of them (93%) developed DSA post-transplant (p = 0.001). Conclusion: These data showed that patients positive for sCD30 contents are at high risk for the development of DSA and AR post-transplant regardless of their pre-transplant PRA.

Original languageEnglish (US)
Pages (from-to)461-464
Number of pages4
JournalClinical Transplantation
Volume20
Issue number4
DOIs
StatePublished - Jul 2006

Fingerprint

Chronic Kidney Failure
Antibodies
Transplants
Tissue Donors
Serum
Calcineurin
Graft Rejection
Immunosuppressive Agents
Retrospective Studies
Kidney
Biopsy

Keywords

  • Acute rejection
  • Panel reactive antibodies
  • Renal transplantation
  • sCD30

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Soluble CD30 concentrations in ESRD patients with and without panel reactive HLA antibodies. / Vaidya, Smita; Partlow, David; Barnes, Titus; Thomas, Phillip; Gugliuzza, Kristene.

In: Clinical Transplantation, Vol. 20, No. 4, 07.2006, p. 461-464.

Research output: Contribution to journalArticle

Vaidya, Smita ; Partlow, David ; Barnes, Titus ; Thomas, Phillip ; Gugliuzza, Kristene. / Soluble CD30 concentrations in ESRD patients with and without panel reactive HLA antibodies. In: Clinical Transplantation. 2006 ; Vol. 20, No. 4. pp. 461-464.
@article{230866da3a4946bea091ac00054d5820,
title = "Soluble CD30 concentrations in ESRD patients with and without panel reactive HLA antibodies",
abstract = "Background: In this retrospective study we compared accuracy of panel reactive antibodies (PRA) with serum soluble CD30 (sCD30) contents in predicting acute rejection crisis post-renal transplant. Methods: Pre-transplant sera from 115 patients were evaluated for their PRA and sCD30 concentrations. All patients received calcineurin inhibitorbased immunosuppressive therapy. Objective measurements for rejection were biopsy-proven acute rejection (AR) episodes within first six months of the transplant. Post-transplant sera of patients with AR were tested for the presence of donor-specific HLA antibodies (DSA). Results: Overall AR rate was 16{\%} (18/115). Patients positive for PRA and sCD30 tests were at significantly higher risk for AVR compared with those patients negative for both the tests (36{\%} vs. 5{\%}, p = 0.01). Among negative PRA patients risk for AR was significantly elevated if they were also tested positive for sCD30 concentrations (21{\%} vs. 5{\%}, p = 0.04). Of the 18 patients with AR, 14 were positive for sCD30, and 13 of them (93{\%}) developed DSA post-transplant (p = 0.001). Conclusion: These data showed that patients positive for sCD30 contents are at high risk for the development of DSA and AR post-transplant regardless of their pre-transplant PRA.",
keywords = "Acute rejection, Panel reactive antibodies, Renal transplantation, sCD30",
author = "Smita Vaidya and David Partlow and Titus Barnes and Phillip Thomas and Kristene Gugliuzza",
year = "2006",
month = "7",
doi = "10.1111/j.1399-0012.2006.00506.x",
language = "English (US)",
volume = "20",
pages = "461--464",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Soluble CD30 concentrations in ESRD patients with and without panel reactive HLA antibodies

AU - Vaidya, Smita

AU - Partlow, David

AU - Barnes, Titus

AU - Thomas, Phillip

AU - Gugliuzza, Kristene

PY - 2006/7

Y1 - 2006/7

N2 - Background: In this retrospective study we compared accuracy of panel reactive antibodies (PRA) with serum soluble CD30 (sCD30) contents in predicting acute rejection crisis post-renal transplant. Methods: Pre-transplant sera from 115 patients were evaluated for their PRA and sCD30 concentrations. All patients received calcineurin inhibitorbased immunosuppressive therapy. Objective measurements for rejection were biopsy-proven acute rejection (AR) episodes within first six months of the transplant. Post-transplant sera of patients with AR were tested for the presence of donor-specific HLA antibodies (DSA). Results: Overall AR rate was 16% (18/115). Patients positive for PRA and sCD30 tests were at significantly higher risk for AVR compared with those patients negative for both the tests (36% vs. 5%, p = 0.01). Among negative PRA patients risk for AR was significantly elevated if they were also tested positive for sCD30 concentrations (21% vs. 5%, p = 0.04). Of the 18 patients with AR, 14 were positive for sCD30, and 13 of them (93%) developed DSA post-transplant (p = 0.001). Conclusion: These data showed that patients positive for sCD30 contents are at high risk for the development of DSA and AR post-transplant regardless of their pre-transplant PRA.

AB - Background: In this retrospective study we compared accuracy of panel reactive antibodies (PRA) with serum soluble CD30 (sCD30) contents in predicting acute rejection crisis post-renal transplant. Methods: Pre-transplant sera from 115 patients were evaluated for their PRA and sCD30 concentrations. All patients received calcineurin inhibitorbased immunosuppressive therapy. Objective measurements for rejection were biopsy-proven acute rejection (AR) episodes within first six months of the transplant. Post-transplant sera of patients with AR were tested for the presence of donor-specific HLA antibodies (DSA). Results: Overall AR rate was 16% (18/115). Patients positive for PRA and sCD30 tests were at significantly higher risk for AVR compared with those patients negative for both the tests (36% vs. 5%, p = 0.01). Among negative PRA patients risk for AR was significantly elevated if they were also tested positive for sCD30 concentrations (21% vs. 5%, p = 0.04). Of the 18 patients with AR, 14 were positive for sCD30, and 13 of them (93%) developed DSA post-transplant (p = 0.001). Conclusion: These data showed that patients positive for sCD30 contents are at high risk for the development of DSA and AR post-transplant regardless of their pre-transplant PRA.

KW - Acute rejection

KW - Panel reactive antibodies

KW - Renal transplantation

KW - sCD30

UR - http://www.scopus.com/inward/record.url?scp=33745589757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745589757&partnerID=8YFLogxK

U2 - 10.1111/j.1399-0012.2006.00506.x

DO - 10.1111/j.1399-0012.2006.00506.x

M3 - Article

VL - 20

SP - 461

EP - 464

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 4

ER -